Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial
Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicentre trial
复制标题
DOI：
10.3851/imp3169
复制
发表时间：
2018-01-01
影响因子：
1.2
通讯作者：
Lee, Byung Seok
中科院分区：
文献类型：
--
作者：
Lee, Sae Hwan;Cheon, Gab Jin;Lee, Byung Seok
背景资料：完全病毒学应答与慢性B型肝炎患者的长期结局和预防新出现的HBV突变密切相关。我们的目的是评估与恩替卡韦-阿德福韦酯（ETV-ADV）联合治疗相比，富马酸替诺福韦酯（TDF）单药治疗对长期拉米夫定-阿德福韦酯（LAM-ADV）治疗核苷类似物耐药的慢性乙型肝炎（B.）反应不佳的患者的疗效。方法：患者（n=60）被随机分为TDF单药治疗或ETV-ADV联合治疗96周。所有患者均存在rt 204 I/V变异，且在LAM-ADV治疗期间血清HBV DNA均>60 IU/ml。主要终点是完全病毒学应答（HBV DNA
Background: A complete virological response is closely related to the long-term outcome of patients with chronic hepatitis B and prevention of emerging HBV mutations. We aimed to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy compared to entecavir-adefovir dipivoxil (ETV-ADV) combination therapy in patients with suboptimal responses to long-term lamivudine-adefovir dipivoxil (LAM-ADV) therapy for nucleoside analogue-resistant chronic hepatitis B.Methods: Patients (n=60) were randomized to TDF monotherapy or ETV-ADV combination therapy for 96 weeks. All patients had the rt204I/V mutation and serum HBV DNA was measured (>60 IU/ml) during LAM-ADV therapy. The primary end point was a complete virological response (HBV DNA